Generic Itovebi Availability

Last updated on Jun 11, 2025.

Itovebi is a brand name of inavolisib, approved by the FDA in the following formulation(s):

ITOVEBI (inavolisib - tablet;oral)

• Manufacturer: GENENTECH INC
  Approval date: October 10, 2024
  Strength(s): 3MG ^[RLD], 9MG ^[RLD]

Is there a generic version of Itovebi available?

No. There is currently no therapeutically equivalent version of Itovebi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Itovebi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Benzoxazepin oxazolidinone compounds and methods of use
  Patent 10,851,091
  Issued: December 1, 2020
  Inventor(s): Braun; Marie-Gabrielle et al.
  Assignee(s): Genentech, Inc. (South San Francisco, CA)
  

  Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: ##STR00001## or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

  Patent expiration dates:

  • July 1, 2036
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
  Patent 11,028,100
  Issued: June 8, 2021
  Inventor(s): Chakravarty; Paroma et al.
  Assignee(s): Genentech, Inc. (South San Francisco, CA)
  

  The present invention relates to crystalline polymorph forms of (S)-2-((2-((S)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide (GDC-0077), having the structure, Formula I: ##STR00001## or stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, and processes of preparing the polymorph forms.

  Patent expiration dates:

  • April 26, 2038
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Benzoxazepin oxazolidinone compounds and methods of use
  Patent 11,760,753
  Issued: September 19, 2023
  Inventor(s): Braun; Marie-Gabrielle et al.
  Assignee(s): Genentech, Inc. (South San Francisco, CA)
  

  Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: ##STR00001## or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

  Patent expiration dates:

  • July 1, 2036
    
    ✓ 
    Patent use: COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY
• Benzoxazepin P13K inhibitor compounds and methods of use
  Patent 8,242,104
  Issued: August 14, 2012
  Inventor(s): Blaquiere; Nicole et al.
  Assignee(s): F. Hoffman-La Roche AG (Basel, CH)
  

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z.sup.1 is CR.sup.1 or N; Z.sup.2 is CR.sup.2 or N; Z.sup.3 is CR.sup.3 or N; Z.sup.4 is CR.sup.4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001##

  Patent expiration dates:

  • September 27, 2030
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
• Benzoxazepin PI3K inhibitor compounds and methods of use
  Patent 8,343,955
  Issued: January 1, 2013
  Inventor(s): Blaquiere; Nicole et al.
  Assignee(s): Genentech, Inc. (South San Francisco, CA)
  

  Benzoxazepin compounds of Formula I, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, wherein: Z.sup.1 is CR.sup.1 or N; Z.sup.2 is CR.sup.2 or N; Z.sup.3 is CR.sup.3 or N; Z.sup.4 is CR.sup.4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring fused to the benzoxepin ring, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001##

  Patent expiration dates:

  • September 27, 2030
    
    ✓ 
    Patent use: COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY
• Benzoxazepin oxazolidinone compounds and methods of use
  Patent 9,650,393
  Issued: May 16, 2017
  Inventor(s): Braun; Marie-Gabrielle et al.
  Assignee(s): Genentech, Inc. (South San Francisco, CA)
  

  Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: ##STR00001## or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

  Patent expiration dates:

  • July 1, 2036
    
    ✓ 
    Patent use: COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY
    ✓ 
    Drug substance
    ✓ 
    Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:

  • October 10, 2029 - NEW CHEMICAL ENTITY

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer